Top

Journal of Cancer Research and Clinical Oncology

Published in:

09-07-2022 | Vaccination | Research

Seroprevalence study prior and post vaccination in cancer patients in principality of Andorra (COVONCO study)

Authors: Cristina Royo-Cebrecos, Ïa Robert-Montaner, David Vilanova, Eva Bailles, Jordi Serrano-Pons, Oliver Valero, Josep Maria Buldon, Leticia Bermudez-de-Castro, Eva Mahia, Jaume Pujadas, Francesc Cobo, Josep Maria Piqué, Santiago Albiol

Published in: Journal of Cancer Research and Clinical Oncology | Issue 7/2023

Abstract

Background

COVID-19 serologic response in patients with cancer may be lower than in the general population and may be influenced by the type of tumor or anticancer treatment. This study aims to analyze serological response prior and after vaccination of COVID-19 within the oncological population in Andorra. We set out to identify risk factors for a higher or lower serological response.

Patients and methods

Observational, unicentric, prospective cohort study of oncologic patients in Andorra. We calculated the seroprevalence of antibodies against SARS-CoV-2 (May 2020–June 2021) and analyzed the main demographic, oncologic features and factors associated with being seropositive.

Results

A total of 373 patients were analyzed, mainly with solid tumours (n = 334, 89.5%). At baseline, seroprevalence was 13%, increasing during follow-up to 19%; lower seroprevalence was observed in patients with hematologic malignancies (2.6% vs 14.2%; p = 0.041) and patients receiving biological therapies (0% vs 15%, p = 0.005). In the overall seroprevalence analysis, women (23% vs 11.9%; p = 0.006) and tumour-free patients (p = 0.034) showed higher seroprevalence. The multivariable analysis showed that odds of being seropositive were higher among women (OR: 2.44, 95% CI 1.28–4.64), and patients who underwent surgery (OR: 3.35, 95% CI 1.10–10.20). About 80% of the cohort received at least one dose of COVID-19 vaccination, showing a higher seroprevalence of patients who received ChAdOx1-S than those who received BNT162b2 (24.4% vs 6.4%: p = 0.001).

Conclusion

The seroprevalence of antibodies against SARS-COV-2 in oncologic patients in Andorra was higher among females and patients who received hormonal therapy and surgery while patients with hematologic malignancies and biologic therapies showed lower seropositivity without finding differences in the type of tumour or anticancer treatment.

Aschele C, Negru ME, Pastorino A, Cavanna L, Zagonel V, Barone-Adesi F et al (2021) Incidence of SARS-CoV-2 infection among patients undergoing active antitumor treatment in Italy. JAMA Oncol 7(2):304CrossRefPubMed

Bird S, Panopoulou A, Shea RL, Tsui M, Saso R, Sud A et al (2021) Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma. Lancet Haematol 8(6):e389–e392CrossRefPubMedPubMedCentral

Cabezón-Gutiérrez L, Custodio-Cabello S, Palka-Kotlowska M, Oliveros-Acebes E, García-Navarro MJ, Khosravi-Shahi P (2020) Seroprevalence of SARS-CoV-2–specific antibodies in cancer outpatients in Madrid (Spain): A single center, prospective, cohort study and a review of available data. Cancer Treat Rev 90:102102CrossRefPubMedPubMedCentral

Cantini L, Bastianelli L, Lupi A, Pinterpe G, Pecci F, Belletti G et al (2021) Seroprevalence of sars-cov-2–specific antibodies in cancer patients undergoing active systemic treatment: A single-center experience from the marche region, italy. J Clin Med 10(7):1503CrossRefPubMedPubMedCentral

Chowdhury O, Bruguier H, Mallett G, Sousos N, Crozier K, Allman C et al (2021) Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms. Br J Haematol 194(6):1010–1015CrossRefPubMedPubMedCentral

Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z et al (2020) Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak. Cancer Discovery. https://doi.org/10.1158/2159-8290.CD-20-0422CrossRefPubMedPubMedCentral

Daniel P, Oran A, Eric J, Topol M (2020) Prevalence of Asymptomatic SARS-CoV-2 Infection. Ann Int Med

Gavriatopoulou M, Terpos E, Kastritis E, Briasoulis A, Gumeni S, Ntanasis-Stathopoulos I et al (2021) Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine. Clin Experim Med. https://doi.org/10.1007/s10238-021-00746-4CrossRef

Guven DC, Sahin TK, Kilickap S, Uckun FM (2021) Antibody responses to COVID-19 vaccination in cancer: a systematic review. Front Oncol 4:11

Jaillon S, Berthenet K, Garlanda C (2019) Sexual dimorphism in innate immunity. Clin Rev Allergy Immunol 56(3):308–321CrossRefPubMed

Liang W, Guan W, Chen R, Wang W, Li J, Xu K et al (2020) Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 21(3):335–337CrossRefPubMedPubMedCentral

Lim SH, Campbell N, Johnson M, Joseph-Pietras D, Collins GP, O’Callaghan A et al (2021) Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma. Lancet Haematol 8(8):e542–e544CrossRefPubMedPubMedCentral

Liu H, Yang D, Chen X, Sun Z, Zou Y, Chen C et al (2021) The effect of anticancer treatment on cancer patients with COVID-19: A systematic review and meta-analysis. Cancer Med 10(3):1043–1056CrossRefPubMed

Miyashita H, Mikami T, Chopra N, Yamada T, Chernyavsky S, Rizk D et al (2020) Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City. Ann Oncol 31(8):1088–1089CrossRefPubMed

Montopoli M, Zumerle S, Vettor R, Rugge M, Zorzi M, Catapano CV et al (2020) Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532). Ann Oncol 31(8):1040–1045CrossRefPubMed

Pinato DJ, Zambelli A, Aguilar-Company J, Bower M, Sng CCT, Salazar R et al (2020) Clinical portrait of the SARS-CoV-2 epidemic in european patients with cancer. Cancer Discov 10(10):1465–1474CrossRefPubMedPubMedCentral

Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M et al (2020) Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. The Lancet 396(10250):535–544CrossRef

Royo-Cebrecos C, Vilanova D, López J, Arroyo V, Pons M, Francisco G et al (2021) Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra. Lancet Region Health Europe. https://doi.org/10.1016/j.lanepe.2021.100119CrossRefPubMed

Saini KS, Tagliamento M, Lambertini M, McNally R, Romano M, Leone M et al (2020) Mortality in patients with cancer and coronavirus disease: A systematic review and pooled analysis of 52 studies. Eur J Cancer. https://doi.org/10.1016/j.ejca.2020.08.011CrossRefPubMedPubMedCentral

Salje H, Tran Kiem C, Lefrancq N, Courtejoie N, Bosetti P, Paireau J et al (2020) Estimating the burden of SARS-CoV-2 in France. Science 369(6500):208–211CrossRefPubMedPubMedCentral

Snoeck CJ, Vaillant M, Abdelrahman T, Satagopam VP, Turner JD, Beaumont K, et al. Prevalence of SARS-CoV-2 infection in the Luxembourgish population-the CON-VINCE study. Available from: https://doi.org/10.1101/2020.05.11.20092916

Solodky ML, Galvez C, Russias B, Detourbet P, N’Guyen-Bonin V, Herr A-L et al (2020) Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19. Ann Oncol 31(8):1087–1088CrossRefPubMed

Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H et al (2020) Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. The Lancet 396(10247):313–319CrossRef

Subbiah V (2020) A global effort to understand the riddles of COVID-19 and cancer. Nature Cancer 1(10):943–945CrossRefPubMed

Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K et al (2021) Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell 39(8):1081-1090.e2CrossRefPubMedPubMedCentral

Tran S, Truong TH, Narendran A (2021) Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis. Eur J Cancer 159:259–274CrossRefPubMedPubMedCentral

Ueda M, Martins R, Hendrie PC, McDonnell T, Crews JR, Wong TL et al (2020) Managing cancer care during the COVID-19 pandemic: agility and collaboration toward a common goal. J Natl Comprehens Cancer Network. https://doi.org/10.6004/jnccn.2020.7560CrossRef

Wang C, Horby PW, Hayden FG, Gao GF (2020) A novel coronavirus outbreak of global health concern. Lancet. 395(10223):470–473. https://doi.org/10.1016/S0140-6736(20)30185-9CrossRefPubMedPubMedCentral

WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020 [Internet]. [cited 2020 Jun 2]. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020

Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC (2020) Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19). JAMA 324(8):782CrossRefPubMed

Wise-Draper TM, Desai A, Elkrief A, Rini BI, Flora DB, Bowles DW et al (2020) LBA71 Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A CCC19 registry analysis. Ann Oncol. https://doi.org/10.1016/j.annonc.2020.08.2312CrossRef

World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report. Available at: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---22-february-2022.

Xu X, Sun J, Nie S, Li H, Kong Y, Liang M et al (2020) Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. Nat Med 26(8):1193–1195CrossRefPubMed

Yu J, Ouyang W, Chua MLK, Xie C (2020) SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol 6(7):1108CrossRefPubMedPubMedCentral

Zambelli A, Fotia V, Bosetti T, Negrini G, di Croce A, Moro C, Poletti PL, Bettini AC, Arnoldi E, Messina C, Merelli B, Callegaro AP, Chiudinelli L, Mosconi S, Tondini C (2020) 1676MO Prevalence and clinical impact of asymptomatic or mildly symptomatic SARSCoV-2 infection among actively treated cancer patients during COVID-19 pandemic in Italy. Ann Oncol 31:S994. Available from: http://www.annalsofoncology.org/article/S0923753420417375/fulltext

Title: Seroprevalence study prior and post vaccination in cancer patients in principality of Andorra (COVONCO study)
Authors: Cristina Royo-Cebrecos
Ïa Robert-Montaner
David Vilanova
Eva Bailles
Jordi Serrano-Pons
Oliver Valero
Josep Maria Buldon
Leticia Bermudez-de-Castro
Eva Mahia
Jaume Pujadas
Francesc Cobo
Josep Maria Piqué
Santiago Albiol
Publication date: 09-07-2022
Publisher: Springer Berlin Heidelberg
Keywords: Vaccination
SARS-CoV-2
COVID-19
Published in: Journal of Cancer Research and Clinical Oncology / Issue 7/2023
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-022-04141-8

Evaluation of different imaging modalities for axillary lymph node staging in breast cancer patients to provide a personalized and optimized therapy algorithm

Open Access
Breast Cancer
Original Research

The role of microRNA-30c in targeting interleukin 6, as an inflammatory cytokine, in the mesenchymal stem cell: a therapeutic approach in colorectal cancer

Cytokines
Original Research

The Ala134Thr variant in TMEM176B exerts a beneficial role in colorectal cancer prognosis by increasing NLRP3 inflammasome activation

Colorectal Cancer
Original Research

Improved preoperative risk stratification in endometrial carcinoma patients: external validation of the ENDORISK Bayesian network model in a large population-based case series

Open Access
Endometrial Cancer
Original Research

Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis

Vaccination
Original Research

Prognosis of different extrathoracic metastasis patterns in patients with M1c lung adenocarcinoma receiving immunotherapy

Metastasis
Original Research

Keynote webinar | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Watch now

Keynote webinar | Spotlight on adolescent vaping

Live
Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET

Prof. Ann McNeill

Dr. Debbie Robson

Benji Horwell

Developed by: Springer Medicine

Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty in Geriatric Patients
On-demand webinar

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft

Prof. Barbara C. van Munster

Prof. Mirko Petrovic

Developed by: Springer Medicine

Watch now

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on adolescent vaping

Springer Medicine

Abstract

Background

Patients and methods

Results

Conclusion

Please log in to get access to this content